Skip to main content
SpringerLink
Log in

Pancreatic Cancer

  • Chapter
  • First Online:
Handbook of Evidence-Based Radiation Oncology

  • 2668 Accesses

Abstract

This chapter will discuss the epidemiology, workup, management, treatment, and follow-up for pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(22):2654–68.

    Article  Google Scholar 

  • Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26(36):5918–22.

    Article  Google Scholar 

  • Chauffert B, Momex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.

    Article  CAS  Google Scholar 

  • Cloyd JM, Crane CH, Koay EJ, et al. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016;122(17):2671–9.

    Article  CAS  Google Scholar 

  • Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496–502.

    Article  CAS  Google Scholar 

  • GITSG. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59(12):2006–10.

    Article  Google Scholar 

  • Goodman KA, Regine WF, Dawson LA, et al. Radiation therapy Oncology group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys. 2012;83(3):901–8.

    Article  Google Scholar 

  • Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–53.

    Article  CAS  Google Scholar 

  • Hazard L, Tward JD, Szabo A, et al. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the surveillance, epidemiology, and end results (SEER) registry data. Cancer. 2007;11(10):2191–201.

    Article  Google Scholar 

  • Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17(4):981–90.

    Article  Google Scholar 

  • Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally-advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J Clin Oncol. 2007;25:326–31.

    Article  CAS  Google Scholar 

  • Kalser M, Ellenberg S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903. Erratum in: Arch Surg 1986;121(9):1045

    Article  CAS  Google Scholar 

  • Katz SJ. Jama Surg. 2016;151(8):e161(3).

    Google Scholar 

  • Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guidelines. J Clin Oncol. 2016;34(21):2541–56.

    Article  Google Scholar 

  • Kim EJ, Ben-Josef E, Herman JM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119(15):2692–700.

    Article  CAS  Google Scholar 

  • Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82. discussion 782-784

    Article  CAS  Google Scholar 

  • Kooby DA, Gillespie TW, Liu Y, et al. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol. 2013;20(11):3634–42.

    Article  Google Scholar 

  • Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110(1):47–55.

    Article  Google Scholar 

  • Loehrer PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative Oncology group trial. J Clin Oncol. 2011;29:4105–12.

    Article  CAS  Google Scholar 

  • Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54(7):979–85.

    Article  CAS  Google Scholar 

  • Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the gastrointestinal tumor study group. Cancer. 1981;48(8):1705–10.

    Article  CAS  Google Scholar 

  • Morganti AG, Falconi M, van Stiphout RGPM, et al. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;90(4):911–7.

    Article  Google Scholar 

  • Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicenter, randomized, phase 2 trial. Lancet Oncol. 2013;14:317–26.

    Article  CAS  Google Scholar 

  • Murphy JD, Adusumilli S, Griffith KA, et al. Full dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:801–8.

    Article  CAS  Google Scholar 

  • Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.

    Article  CAS  Google Scholar 

  • Neoptolemos JP, Stocken DD, Friess H, et al.; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10. Erratum in: N Engl J Med 2004; 351(7):726.

    Google Scholar 

  • Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.

    Article  CAS  Google Scholar 

  • Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicenter, open-label, randomized, phase 3 trial. Lancet. 2017. https://doi.org/10.1016/S0140-6736(16)32409-6.

    Article  CAS  Google Scholar 

  • Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer (CONKO-001). JAMA. 2007;297(3):267–76.

    Article  CAS  Google Scholar 

  • Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.

    Article  CAS  Google Scholar 

  • Petrelli F, Comito T, Ghidini A, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017;97(2):313–22.

    Article  Google Scholar 

  • Pollom EL, Alagappan M, von Eyben R, et al. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys. 2014;90(4):918–25.

    Article  Google Scholar 

  • Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. JAMA. 2008;299(9):1019–26.

    Article  CAS  Google Scholar 

  • Smeenk HG, van Eijck CHJ, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of the EORTC trial 40891. Ann Surg. 2007;246(5):734–40.

    Article  Google Scholar 

  • Tyvin R, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol. 2004;27:51–6.

    Article  Google Scholar 

  • Van Laethem J-L, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28(29):4450–6.

    Article  Google Scholar 

  • Yovino S, Poppe M, Jabbour S, et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys. 2011;79(1):158–62.

    Article  Google Scholar 

Download references

Acknowledgment

We thank Jennifer S. Yu MD, PhD, Joy Coleman MD, and Jeanne Marie Quivey MD, FACR, for their work on the prior edition of this chapter.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of California San Francisco, Marin General Hospital, San Francisco, CA, USA

    Jennifer S. Chang

  2. Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA

    Mekhail Anwar

Authors
  1. Jennifer S. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mekhail Anwar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer S. Chang .

Editor information

Editors and Affiliations

  1. The Oregon Clinic, Providence St. Vincent Medical Center, Portland, OR, USA

    Eric K. Hansen

  2. Department of Radiation Oncology, University of California, San Franc, SAN FRANCISCO, CA, USA

    Mack Roach III

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chang, J.S., Anwar, M. (2018). Pancreatic Cancer. In: Hansen, E., Roach III, M. (eds) Handbook of Evidence-Based Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-62642-0_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62642-0_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62641-3

  • Online ISBN: 978-3-319-62642-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation